 | |
| Clinical data | |
|---|---|
| Other names | 1,2,3,4-Tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quinoline |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H13F3N2O |
| Molar mass | 294.277 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LG-120907 is anonsteroidal antiandrogen (NSAA) of thequinoline group which was developed byLigand Pharmaceuticals along withselective androgen receptor modulators (SARMs) likeLG-121071 and was never marketed.[1][2][3][4] The drug is a high-affinityantagonist of theandrogen receptor (AR) with a Ki value of 26 nM and has been found to inhibitgrowth of theventral prostate andseminal vesicles in male rats without increasing circulating levels ofluteinizing hormone ortestosterone.[1][2][3] However, thistissue selectivity has not been assessed in humans.[5] LG-120907 isorally active and shows greater oralpotency than thearylpropionamide NSAAflutamide.[1][3][4]
The 7-fluoroderivative of LG-120907,LG-105, is also a potent NSAA, and appears to possess greater potency in comparison.[3] Conversely, the 6-ethyl, 8-didesmethylanalogue of LG-120907, LG-121071, is a SARM with potentandrogenic activity equivalent to that ofdihydrotestosterone (DHT).[1][3]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |